Bionano Genomics, Inc.

NCM: BNGO
Live Quote

📈 ZcoreAI Score

Our AI model analyzes Bionano Genomics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.

Get BNGO Z-Score →

About Bionano Genomics, Inc.

Healthcare Medical Instruments & Supplies
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for analysis and interpretation of genomic data from microarray and sequencing data for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

📊 Fundamental Analysis

Bionano Genomics, Inc. demonstrates a profit margin of -92.6%, which is below the sector average, suggesting competitive pressure.

The company recently reported -2.6% revenue growth, which is negative, indicating a recent decline in revenue.

Return on Equity (ROE) is -66.2%, which indicates that capital utilization is currently under pressure.

At a current price of $1.13, BNGO currently trades near the bottom of its 52-week range (2%), indicating potential value or weakness (Range: $1.06 - $5.50).

🏥 Financial Health

🔴 Profit Margin Weak
Debt/Equity Excellent
🔴 Revenue Growth Weak
🔴 Return on Equity Weak
🔴 Beta (Risk) High Volatility

Key Financials

Market Cap
$12.53M
Trailing P/E
--
Forward P/E
-1.02
Beta (5Y)
1.60
52W High
$5.50
52W Low
$1.06
Avg Volume
358K
Day High
Day Low
Get BNGO Z-Score on Dashboard 🚀